Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Earnings and Raised Guidance

Stock Track11-03

TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in its stock price during Monday's pre-market trading, despite reporting impressive third-quarter earnings and raising its full-year revenue guidance. This unexpected downturn comes in the face of what appears to be overwhelmingly positive financial news for the biopharmaceutical company.

The company reported stellar Q3 2025 results, with earnings per share of $2.43, significantly surpassing the analyst consensus estimate of $0.22. This represents a remarkable 12,050% increase from the same period last year. Revenue for the quarter came in at $161.709 million, beating estimates of $152.169 million and marking a 92.79% year-over-year growth. The strong performance was primarily driven by robust sales of BRIUMVI, their flagship multiple sclerosis treatment.

Adding to the positive news, TG Therapeutics raised its full-year 2025 global revenue target to $600 million and increased its BRIUMVI U.S. net revenue target to $585 million, citing strong market demand. The company also completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, investors appear to be reacting negatively, possibly due to profit-taking after recent gains or concerns about the sustainability of the rapid growth rate. The market's response underscores the complex factors that can influence stock prices beyond fundamental financial performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160557542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160557542","market":"nz","top_or_hot":-1,"title":"Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Earnings and Raised Guidance","media":"Stock Track","content":"<p>TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in its stock price during Monday's pre-market trading, despite reporting impressive third-quarter earnings and raising its full-year revenue guidance. This unexpected downturn comes in the face of what appears to be overwhelmingly positive financial news for the biopharmaceutical company.</p>\n\n<p>The company reported stellar Q3 2025 results, with earnings per share of $2.43, significantly surpassing the analyst consensus estimate of $0.22. This represents a remarkable 12,050% increase from the same period last year. Revenue for the quarter came in at $161.709 million, beating estimates of $152.169 million and marking a 92.79% year-over-year growth. The strong performance was primarily driven by robust sales of BRIUMVI, their flagship multiple sclerosis treatment.</p>\n\n<p>Adding to the positive news, TG Therapeutics raised its full-year 2025 global revenue target to $600 million and increased its BRIUMVI U.S. net revenue target to $585 million, citing strong market demand. The company also completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, investors appear to be reacting negatively, possibly due to profit-taking after recent gains or concerns about the sustainability of the rapid growth rate. The market's response underscores the complex factors that can influence stock prices beyond fundamental financial performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Earnings and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | TG Therapeutics Plummets 5.66% Despite Strong Q3 Earnings and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-03 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in its stock price during Monday's pre-market trading, despite reporting impressive third-quarter earnings and raising its full-year revenue guidance. This unexpected downturn comes in the face of what appears to be overwhelmingly positive financial news for the biopharmaceutical company.</p>\n\n<p>The company reported stellar Q3 2025 results, with earnings per share of $2.43, significantly surpassing the analyst consensus estimate of $0.22. This represents a remarkable 12,050% increase from the same period last year. Revenue for the quarter came in at $161.709 million, beating estimates of $152.169 million and marking a 92.79% year-over-year growth. The strong performance was primarily driven by robust sales of BRIUMVI, their flagship multiple sclerosis treatment.</p>\n\n<p>Adding to the positive news, TG Therapeutics raised its full-year 2025 global revenue target to $600 million and increased its BRIUMVI U.S. net revenue target to $585 million, citing strong market demand. The company also completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, investors appear to be reacting negatively, possibly due to profit-taking after recent gains or concerns about the sustainability of the rapid growth rate. The market's response underscores the complex factors that can influence stock prices beyond fundamental financial performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1160557542","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160557542","pubTimestamp":1762180550,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in its stock price during Monday's pre-market trading, despite reporting impressive third-quarter earnings and raising its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc."},"translate_title":"个股追踪|TG Therapeutics暴跌5.66%尽管Q3盈利强劲且指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TGTX":1},"content_text":"TG Therapeutics (NASDAQ: TGTX) experienced a surprising 5.66% plunge in its stock price during Monday's pre-market trading, despite reporting impressive third-quarter earnings and raising its full-year revenue guidance. This unexpected downturn comes in the face of what appears to be overwhelmingly positive financial news for the biopharmaceutical company.\nThe company reported stellar Q3 2025 results, with earnings per share of $2.43, significantly surpassing the analyst consensus estimate of $0.22. This represents a remarkable 12,050% increase from the same period last year. Revenue for the quarter came in at $161.709 million, beating estimates of $152.169 million and marking a 92.79% year-over-year growth. The strong performance was primarily driven by robust sales of BRIUMVI, their flagship multiple sclerosis treatment.\nAdding to the positive news, TG Therapeutics raised its full-year 2025 global revenue target to $600 million and increased its BRIUMVI U.S. net revenue target to $585 million, citing strong market demand. The company also completed a $100 million share repurchase program and authorized an additional $100 million for future repurchases. Despite these encouraging developments, investors appear to be reacting negatively, possibly due to profit-taking after recent gains or concerns about the sustainability of the rapid growth rate. The market's response underscores the complex factors that can influence stock prices beyond fundamental financial performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160557542","isCrawlerRequest":true}